MedCity News April 3, 2024
Marissa Plescia

In a letter, several stakeholders urged the Drug Enforcement Administration to release a revised proposed rule on the virtual prescribing of controlled substances. This comes as Covid-19 flexibilities that allow controlled substances to be prescribed via telehealth without an in-person exam are set to expire at the end of the year.

In an April 2 letter, a group of over 200 stakeholders urged the Drug Enforcement Administration (DEA) to release a revised proposed rule that would “permit and regulate the prescribing of controlled substances through telehealth.” The stakeholders include the Alliance for Connected Care, the American Telemedicine Association, ATA Action, the Consumer Technology Association, the Healthcare Information and Management Systems Society and the Partnership to Advance Virtual Care.

The DEA...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Digital Health, Govt Agencies, Patient / Consumer, Provider, Technology, Telehealth
Related Articles:
Amwell’s Roy Schoenberg talks about telehealth and broader views of virtual care
The telehealth background of Trump's FDA pick: 6 notes
Teladoc expands virtual sitter capabilities
AHA, others urge Congress to act on alternative payment models, avoid physician payment cut
Are telehealth visits for pediatric primary care associated with higher rates of health care utilization?

Share This Article